Bristol-Myers Squibb's third-quarter profit in 2007 doubled from $338 million to $858 million. Revenue increased by 22 percent to $5.05 billion, from $4.15 billion during this period last year. Stock prices rose 94 cents to $29.36.
BMY announces 2007:1Q earnings that show signs of strong recovery from the Plavix debacle of 2006
Stock price drops after talks about a possible acquisition by partner Sanofi-Aventis fall through.
Stock reaches a year-high price of nearly $29 on news of friendly takeover talks between BMY and Sanofi-Aventis, feuled by the recent appointment of James Cornelius (engineer of the Boston Scientific Guidant takeover) as CEO